<SEC-DOCUMENT>0001096906-25-000625.txt : 20250429
<SEC-HEADER>0001096906-25-000625.hdr.sgml : 20250429
<ACCEPTANCE-DATETIME>20250429143256
ACCESSION NUMBER:		0001096906-25-000625
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250429
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250429
DATE AS OF CHANGE:		20250429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		25885858

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20250429.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fil="http://utahmed.com/20250429" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VEM54XX9]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body>
<div style="display:none">
<ix:header>
<ix:hidden>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D250429" id="fact1">0000706698</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D250429" id="fact2">false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="utmd-20250429.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<i:context id="D250429">
<i:entity>
<i:identifier scheme="http://www.sec.gov/CIK">0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2025-04-29</i:startDate>
<i:endDate>2025-04-29</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:14pt Times New Roman;margin:0;text-align:center"><b>UNITED STATES </b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center"><b>Washington, D.C. &#160;20549</b></p>
<p style="font:15pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b>FORM </b><b><ix:nonNumeric name="dei:DocumentType" contextRef="D250429" escape="true" id="ixv-354">8-K</ix:nonNumeric></b></span></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:14pt Times New Roman;margin:0;text-align:center"><b>CURRENT REPORT</b></p>
<p style="font:14pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;text-align:center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">Date of Report (date of earliest event reported): &#160;<b><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D250429" format="ixt:date-monthname-day-year-en" id="ixv-355">April 29, 2025</ix:nonNumeric></b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:14pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D250429" escape="true" id="ixv-356">UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D250429" format="ixt-sec:stateprovnameen" id="ixv-357">Utah</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D250429" escape="true" id="ixv-358">000-12575</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:11pt"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D250429" escape="true" id="ixv-359">87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(State or other jurisdiction of</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Commission File Number)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(IRS Employer</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">incorporation or organization)</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">Identification No.)</p>
</td></tr>
<tr><td valign="top" style="width:31.62%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D250429" escape="true" id="ixv-360">7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D250429" escape="true" id="ixv-361">Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D250429" format="ixt-sec:stateprovnameen" id="ixv-362">Utah</ix:nonNumeric></b></span></p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D250429" escape="true" id="ixv-363">84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Address of principal executive offices)</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Zip code)</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:11pt Times New Roman;margin:0">Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:10pt Times New Roman;margin:0;text-align:center"><span style="font-size:12pt"><b>Phone: </b><b>(</b><b><ix:nonNumeric name="dei:CityAreaCode" contextRef="D250429" escape="true" id="ixv-364">801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D250429" escape="true" id="ixv-365">566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan="3" valign="top" style="width:65.82%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.58%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:31.6%"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:12pt Times New Roman;margin:0;text-align:center"><b>n/a</b></p>
</td></tr>
<tr><td colspan="5" valign="top" style="width:100%;padding-left:0.7pt;padding-right:0.7pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="D250429" format="ixt-sec:boolballotbox" id="ixv-366">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="D250429" format="ixt-sec:boolballotbox" id="ixv-367">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="D250429" format="ixt-sec:boolballotbox" id="ixv-368">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="D250429" format="ixt-sec:boolballotbox" id="ixv-369">&#9744;</ix:nonNumeric></p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign="top" style="width:27.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:450.9pt"><p style="font:10pt Times New Roman;margin:0;text-align:right">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D250429" format="ixt-sec:boolballotbox" id="ixv-370">&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr><td colspan="2" valign="top" style="width:478.8pt"><p style="font:10pt Times New Roman;margin:0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><hr style="page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0"/><p style="line-height:0;margin:0"></p>
<hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/><p style="font:11pt Times New Roman;margin:0"><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated April 29, 2025. &#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt">&#160;</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:72pt;text-align:justify">The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style="font:12pt Times New Roman;margin:0;margin-left:90pt">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0"><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">The following is filed as an exhibit to this report: &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Exhibit</b></p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Number*</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Title of Document</b></p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000"><p style="font:9pt Times New Roman;margin:0;text-align:center">&#160;</p>
<p style="font:9pt Times New Roman;margin:0;text-align:center"><b>Location</b></p>
</td></tr>
<tr><td valign="top" style="background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center"><b>Item 99.1</b></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><span style="font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF"><a href="utmd_ex99z1.htm" style="text-decoration:none">Financial information for Utah Medical Prod</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ucts, Inc. for the three months ended March 31, 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and forward-loo</a><a href="utmd_ex99z1.htm" style="text-decoration:none">king statements relating to 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none"> and beyond as present</a><a href="utmd_ex99z1.htm" style="text-decoration:none">ed in a press release dated April 29, 2025</a><a href="utmd_ex99z1.htm" style="text-decoration:none">.</a></span></p>
</td><td valign="top" style="background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:12.56%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:69.22%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0">&#160;</p>
</td><td valign="top" style="width:2.62%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:12.98%;padding-left:5.75pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">This filing</p>
</td></tr>
</table>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">_______________________________________</p>
<p style="font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify"><kbd style="position:absolute;font:9pt Times New Roman;margin-left:-18pt">*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:center"><b>SIGNATURES</b></p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</div>
<div style="margin-left:72pt"><table style="border-collapse:collapse"><tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify"><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td colspan="2" valign="top" style="width:244.75pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Dated:  April 29, 2025</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">By:</p>
</td><td valign="top" style="width:218.05pt;border-bottom:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign="top" style="width:234.05pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:26.7pt;padding-left:0.7pt;padding-right:5.75pt"><p style="font:11pt Times New Roman;margin:0;text-align:justify">&#160;</p>
</td><td valign="top" style="width:218.05pt;border-top:0.5pt solid #000000"><p style="font:11pt Times New Roman;margin:0;text-align:justify">Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style="margin-left:72pt;width:468pt"><hr style="border:0;height:0;width:0;margin:14pt 0 0 0"/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND FORWARD-LOOKING STATEMENTS RELATING TO 2025 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED APRIL 29, 2025.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VEM54XX9]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><B>EXHIBIT 99.1</B></P>
<P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><B>Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2025</B></P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'>Contact: Brian Koopman (801) 566-1200</KBD><KBD style=margin-left:396pt></KBD>April 29, 2025&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Salt Lake City, Utah &#8211;&nbsp;In the first calendar quarter (1Q) of 2025, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with its previously announced projections for calendar year 2025. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Summary of results</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>The following is a summary comparison of 1Q 2025 with 1Q 2024 income statement measures:</P>
<TABLE style=border-collapse:collapse;width:462.6pt;margin-left:5.4pt><TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;(14.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;(18.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;(18.8%)</P>
</TD></TR>
<TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(23.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;(16.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD></TR>
<TR><TD colspan=4 valign=top style=width:282.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Profit margins in 1Q 2025 compared to 1Q 2024 follow:</P>
</TD><TD valign=top style=width:90pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1Q 2025</P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(JAN &#8211;&nbsp;MAR) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>1Q 2024 </P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>JAN - MAR</FONT></P>
</TD></TR>
<TR><TD colspan=4 valign=top style=width:282.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (gross profits/ sales):</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>57.0%</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>59.7%</P>
</TD></TR>
<TR><TD colspan=4 valign=top style=width:282.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (operating income/ sales):</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>32.5%</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>34.2%</P>
</TD></TR>
<TR><TD colspan=4 valign=top style=width:282.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>EBT Margin (profits before income taxes/ sales):</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>39.7%</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>42.3%</P>
</TD></TR>
<TR><TD colspan=4 valign=top style=width:282.6pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.25pt'>Net Income Margin (profit after taxes/ sales):</P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>31.3% </P>
</TD><TD valign=top style=width:90pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>34.9% </P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated sales in 1Q 2025 were $1,630 lower than in 1Q 2024. &nbsp;OEM sales to PendoTECH were $1,476 lower, representing 91% of the decline. The decline in sales to PendoTECH in the first quarter represented 55% of the 2024-year total sales to PendoTECH. Excluding PendoTECH sales, domestic sales in 1Q 2025 were 9% higher, and sales outside the U.S. (OUS) were 14% lower in USD terms, compared to 1Q 2024. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in &#8220;constant currency&#8221; terms, OUS sales excluding PendoTECH would have been an additional $43 (12% lower than in 1Q 2024). FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2025 and 1Q 2024 follow:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'>1Q 2025</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'>1Q 2024</FONT> &nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.261</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.267</KBD><KBD style=margin-left:297.7pt></KBD> (0.6%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.073</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.083</KBD><KBD style=margin-left:297.7pt></KBD> (0.9%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.628</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.658</KBD><KBD style=margin-left:297.7pt></KBD> (4.5%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.697</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.742</KBD><KBD style=margin-left:297.7pt></KBD> (6.0%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s 1Q 2025 GP at $5,538 was $1,227 lower than 1Q 2024 GP of $6,766. &nbsp;The 18.1% lower GP was the result of 14.4% lower sales combined with a Gross Profit Margin (GPM), GP/revenues, almost three percentage points lower than in 1Q 2024. The lower GPM was due to manufacturing overhead costs which did not decline proportionally to the sales decline. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated OI, which is GP less Operating Expense (OE), in 1Q 2025 at $3,154 (32.5% of sales) was only $730 lower than 1Q 2024 OI of $3,883 (34.2% of sales), despite the $1,227 lower GP. &nbsp;OE in 1Q 2025 were $498 lower than in 1Q 2024 primarily due to $437 lower litigation expenses, which are included in General and Administrative (G&amp;A) portion of OE. &nbsp;The other components of OE, Product </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>Development (R&amp;D) expenses and Sales &amp; Marketing (S&amp;M) expenses, were $112 lower and $88 higher than in 1Q 2024, respectively. The lower R&amp;D expense was related to independent certification of UTMD&#8217;s own biopharma manufacturing pressure sensors in 1Q 2024. &nbsp;&nbsp;</FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Income Before Tax (EBT) had a higher percentage decline than OI because net non-operating income (NOI) in 1Q 2025 was $705 compared to $915 in 1Q 2024. The lower NOI was due to lower interest earned on cash balances and an excise tax levied on share repurchases. Combining the $730 lower OI with $210 lower NOI yielded 1Q 2025 EBT $940 (19.6%) lower than in 1Q 2024. &nbsp;UTMD&#8217;s EBT Margin (EBT/sales) was 39.7% in 1Q 2025 compared to 42.3% in 1Q 2024. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s consolidated income tax provision rate in 1Q 2025 was 21.2% compared to 17.6% in 1Q 2024. An EBT mix difference with a greater share of consolidated EBT generated in the U.S., and an income tax true-up related to repatriation tax payments, caused the provision rate difference. The basic corporate income tax rate for the U.S. (including Utah) is 25.45% and for Ireland on EBT from exports is 12.5%. The higher income tax provision rate on top of the 19.6% lower EBT resulted in 1Q 2025 NI that was 23.1% lower than in 1Q 2024. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>During the four calendar quarters following the end of 1Q 2024, UTMD repurchased 313,120 of its shares in the open market which resulted in 1Q 2025 EPS to only be 16.0% lower than 1Q 2024 despite 23.1% lower NI. There was no dilution from outstanding employee stock options for purposes of calculating diluted EPS in either 1Q 2025 or 1Q 2024. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s March 31, 2025 Balance Sheet, in the absence of debt, remained strong. &nbsp;Despite using $4.4 million in cash during 1Q 2025 to make share repurchases, pay stockholder dividends and purchase new equipment, UTMD&#8217;s March 31, 2025 cash equivalent balance of $83.3 million was slightly higher than the $83.0 million balance three months earlier at December 31, 2024.  Stockholders&#8217; Equity (SE) also remained almost the same at $117 million at the end of 1Q 2025 from three months earlier despite the fact that dividends and share repurchases reduce SE. FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2025 and the end of 1Q 2024 follow:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'>3-31-25</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'>3-31-24</FONT> &nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.289</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.263</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp; 2.1%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.079</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.079</KBD><KBD style=margin-left:297.7pt></KBD>  &nbsp;&nbsp;&nbsp;-&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.624</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.652</KBD><KBD style=margin-left:297.7pt></KBD> (4.4%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.695</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.739</KBD><KBD style=margin-left:297.7pt></KBD>  (5.8%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 1Q 2025 UTMD sales were $1,630 (14.4%) lower than in 1Q 2024. Constant currency sales were $1,588 (14.0%) lower. U.S. domestic sales were 9.8% lower and OUS sales were 19.8% lower. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Domestic sales in 1Q 2025 were $5,583 compared to $6,192 in 1Q 2024. &nbsp;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;Filshie device sales&#8221;, manufactured by Femcare and distributed in the U.S. by UTMD. </P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Direct sales, representing 70% of total domestic sales, were $406 (+11.6%) higher in 1Q 2025 than in 1Q 2024. This was primarily due to recovery of NICU device sales that were harmed in 1Q 2024 from continuing supply chain disruption for raw material components. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>OEM sales, representing 11% of total domestic sales, were $993 (61.3%) lower. U.S. sales to UTMD&#8217;s largest OEM customer, PendoTECH, were $1,047 lower in 1Q 2025 compared to 1Q 2024. &nbsp;All other U.S. OEM sales were $54 (+10.8%) higher. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Domestic Filshie device sales which were just $22 (2.0%) lower in 1Q 2025 compared to 1Q 2024 appear to have stabilized compared to previous declines.  &nbsp;&nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales in 1Q 2025 were $4,127 compared to $5,149 in 1Q 2024. OUS OEM sales to PendoTECH were $429 lower, representing almost half of the decline. In 1Q 2024, UTMD had enjoyed a sporadic Africa distributor order for ES components that did not repeat in 1Q 2025, representing another 25% of the OUS sales decline. OUS sales invoiced in GBP, EUR, AUD and CAD currencies were decreased $43 as a result of changes in FX rates, resulting primarily from a 6.0% weaker CAD and 4.5% weaker AUD. &nbsp;In other words, constant currency OUS sales were $4,170, which was 11.7% lower than in 1Q 2024 excluding PendoTECH. &nbsp;OUS sales invoiced in foreign currencies in 1Q 2025 were $2,944, which was 71% of OUS sales and 30% of total 1Q 2025 consolidated sales. &nbsp;Foreign currency OUS sales in 1Q 2024 were $3,487, which was 68% of OUS sales and 31% of total 1Q 2024 consolidated sales. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing products, including direct labor, raw materials and manufacturing overhead (MOH) expenses, from revenues. &nbsp;MOH includes supervision, engineering, quality assurance, outside services, depreciation of manufacturing equipment, purchasing and freight (including tariffs) for receiving raw materials from vendors. UTMD&#8217;s GP was $1,227 (18.1%) lower in 1Q 2025 than in 1Q 2024. &nbsp;GP declined more than revenues due to lower absorption of MOH costs which, because of their more fixed nature, were only 5.0% lower when sales were 14.4% lower. &nbsp;Management expects revenues to be consistent with 1Q 2025 during the remainder of the year, so it has projected a similar percentage decline in GPM for the year as a whole.  </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. OE is comprised of G&amp;A expenses, S&amp;M expenses and R&amp;D expenses. &nbsp;Consolidated OE were $2,385 in 1Q 2025 (24.6% of sales) compared to $2,882 in 1Q 2024 (25.4% of sales). &nbsp;Ignoring the portion of OE that were litigation expenses and non-cash IIA amortization expenses, OE in 1Q 2025 were $1,570 (16.2% of consolidated sales) compared to $1,628 (14.4% of sales) in 1Q 2024. &nbsp;FX rate differences affecting OUS OE in USD terms in 1Q 2025 compared to 1Q 2024 were minor. All foreign currencies were slightly weaker which reduced 1Q 2025 OUS OE excluding the UK IIA expense just $7 in constant currency. A weaker GBP in 1Q 2025 compared to 1Q 2024 decreased IIA amortization expense also captured in the G&amp;A category in the UK by less than $3. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated G&amp;A expenses were $1,731 (17.8% of sales) in 1Q 2025 compared to $2,205 (19.4% of sales) in 1Q 2024. G&amp;A expenses include litigation costs which were $314 in 1Q 2025 compared to $751 in 1Q 2024. G&amp;A expenses in 1Q 2025 included $501 (5.2% of sales) of non-cash expense from the amortization of IIA resulting from the 2011 Femcare acquisition, which were $504 (4.4% of sales) in 1Q 2024. The decrease was the result of a weaker GBP as the Femcare GBP-denominated expense was the same in both periods. Excluding litigation costs and non-cash Filshie-related IIA amortization expenses, G&amp;A expenses were $916 (9.4% of sales) in 1Q 2025 compared to $950 (8.4% of sales) in 1Q 2024. The change in FX rates decreased 1Q 2025 OUS G&amp;A expenses by less than $8, comprised of decreasing IIA amortization expense by less than $3 and all other G&amp;A expenses by $5. &nbsp;UTMD&#8217;s OIM excluding IIA amortization and litigation expense was 40.9% in 1Q 2025 compared to 45.3% in 1Q 2024.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>S&amp;M expenses were $500 (5.1% of sales) in 1Q 2025 compared to $412 (3.6% of sales) in 1Q 2024. &nbsp;The change in FX rates decreased 1Q 2025 OUS S&amp;M expenses by less than $3. &nbsp;The $91 constant currency increase was due to increases in <A name=_Hlk164328705 />S&amp;M salaries and medical costs for employees on board in both periods, and the timing of trade shows.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>R&amp;D expenses in 1Q 2025 were $155 (1.6% of sales) compared to $266 (2.3% of sales) in 1Q 2024. &nbsp;There were no OUS R&amp;D expenses. The decrease was primarily due to one-time testing and certification of materials required for biopharma sensor manufacturing in 1Q 2024. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In summary, OI in 1Q 2025 was $3,154 (32.5% of sales) compared to $3,883 (34.2% of sales) in 1Q 2024. &nbsp;The 1Q 2025 OI Margin did not decline as much as the GPM due primarily to lower litigation expenses. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT).</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 1Q 2025 EBT was $3,859 (39.7% of sales) compared to $4,798 (42.3% of sales) in 1Q 2024. The almost $940 (19.6%) lower 1Q 2025 EBT compared to 1Q 2024 was the result of $730 lower OI combined with $210 lower NOI. NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. NOI in 1Q 2025 included $153 lower interest income on UTMD&#8217;s cash balances, $32 higher excise tax on share repurchases and $20 less rent received on Ireland unutilized warehouse space. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The EBT of Utah Medical Products, Inc. in the U.S. was $3,546 in 1Q 2025 compared to $2,806 in 1Q 2024. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,393 in 1Q 2025 compared to EUR 1,640 in 1Q 2024. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (663) in 1Q 2025 compared to GBP (101) in 1Q 2024. The 1Q 2025 EBT of Utah Medical Products Canada, Inc. was CAD 107 compared to CAD 66 in 1Q 2024. &nbsp;The differences in the U.S. and UK EBT were accentuated by intercompany transfer of litigation expenses which did not affect consolidated results.  </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2025 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) were $4,652 compared to $5,547 in 1Q 2024, which supports a year 2025 target of $18 million. Management believes that the 1Q 2025 operating performance provides a start that is consistent with achieving its financial performance projections for the calendar year 2025, as previously provided in its Year 2024 SEC 10-K Report. UTMD&#8217;s trailing twelve-month EBITDA as of March 31, 2025 was $18,957. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>NI in 1Q 2025 of $3,041 was 23.1% lower than the NI of $3,956 in 1Q 2024. UTMD&#8217;s NI Margin, NI divided by consolidated sales, was 31.3% in 1Q 2025 and 34.9% in 1Q 2024. The greater NI decline compared to 19.6% lower EBT was due to average consolidated income tax provision rates (as a % of EBT) in 1Q 2025 of 21.2% and 17.6% in 1Q 2024. &nbsp;Although basic corporate income tax rates did not change, the consolidated income tax provision can vary from period-to-period depending on the portion of EBT in sovereignties with differing rates, and a periodic true-up when actual tax returns are filed.  &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EPS in 1Q 2025 at $0.919 were 16.0% lower than the $1.093 in 1Q 2024. &nbsp;UTMD&#8217;s smaller decline in EPS relative to NI was a result of 307,920 fewer diluted shares used to calculate EPS in 1Q 2025 compared to 1Q 2024. Diluted shares were 3,310,248 in 1Q 2025 compared to 3,618,168 in 1Q 2024. &nbsp;Outstanding shares were 3,280,889 at the end of 1Q 2025. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares for shares which were repurchased during the quarter. There was no dilution from unexercised employee options in either 1Q 2025 or 1Q 2024 as the average option exercise prices were above the period-ending closing stock prices. The total number of outstanding unexercised employee and outside director options at March 31, 2025 was 97,779 at an average exercise price of $73.77, including shares awarded but not yet vested. This compares to 97,985 unexercised option shares at the end of 2024 at an average exercise price of $73.77/ share, including shares awarded but not vested. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Outstanding shares at the end of 1Q 2025 were 3,280,889 compared to 3,335,156 at the end of calendar year 2024 and 3,588,336 at the end of 1Q 2024. The difference in outstanding shares at the end of 1Q 2025 compared to the end of 2024 resulted from 54,267 shares repurchased in the open market, with no employee options exercised, during 1Q 2025.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>As previously stated, UTMD repurchased 54,267 of its shares at an average price of $59.35 during 1Q 2025. Because of a time-weighted calculation, the full antidilution impact of the 1Q 2025 repurchases </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>won&#8217;t be felt until 2Q 2025. There were 43,108 share repurchases in 1Q 2024 at an average price of $69.37. No options were awarded in 1Q 2025 or 1Q 2024. During the rest of 2024 after 1Q 2024, 14,600 option shares were awarded to 47 employees at an exercise price of $64.09. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 1Q 2025 was $56.04, down 9% from the $61.47 closing price at the end of 2024. The closing share price at the end of 1Q 2024 was $71.11. </FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD paid $1,017 ($0.305/share) in cash dividends to stockholders in 1Q 2025. UTMD paid $1,089 ($0.300/share) in cash dividends to stockholders in 1Q 2024. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At March 31, 2025 compared to three months earlier at the end of 2024, UTMD&#8217;s cash and investments increased $349 to $83.3 million, despite use of $4.4 million cash to repurchase $3.2 million in shares, pay $1.0 million in stockholder dividends and purchase $0.2 million in additional capital equipment. Compared to a year earlier at March 31, 2024, cash and investments decreased only $10.5 million, during which time UTMD used $24.8 million cash to repurchase $20.2 million in shares, pay $4.2 million in stockholder dividends and purchase $0.4 million in additional capital equipment. At March 31, 2025, net Intangible Assets declined $270 to 13.2% of total consolidated assets from 13.4% on December 31, 2024. &nbsp;The decline in Net Intangible Assets from a year earlier was $1.9 million. &nbsp;Inventories declined $165 from the end of 2024, and $0.6 million from a year earlier. Working capital at the end of 1Q 2025 was $499 lower than at the end of 2024, and $9.6 million lower than at March 31, 2024, as a result of the use of cash. UTMD&#8217;s strong current ratio improved to 22.3 at March 31, 2025 from 19.6 at March 31, 2024. &nbsp;The current ratio at the end of 2024 was 25.6. Consolidated Accounts Receivable (net of allowances) decreased $151 at March 31, 2025 from the end of 2024, but increased $0.4 million compared to March 31, 2024. On a rolling sales quarter basis, the aging of receivables were 36.6 days at the end of 1Q 2025 compared to 40.3 days at the end of 2024, and 28.5 days at the end of March 2024.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>As of March 31, 2025, Stockholders&#8217; Equity (SE) decreased just $10.7 million to $117.0 million compared to a year earlier at March 31, 2024 despite a reduction in SE from the $24.4 million combination of share repurchases and stockholder cash dividends paid during the last twelve months. &nbsp;During 1Q 2025, SE remained essentially the same from the end of 2024 while the company paid $1.0 million in dividends and repurchased $3.2 million in stock, which reduced SE by $4.2 million.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of March 31, 2025 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 22.3&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 1Q 2025 sales activity) = 36.6&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 1Q 2025 CGS) = 1.9&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2025 YTD ROE (before dividends) = 10.4%&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions and potential trade wars, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:12pt Times New Roman;margin:0'><I>Utah Medical Products, Inc.</I></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:-18pt'>INCOME STATEMENT, First Quarter ended March 31 </P>
<P style='font:11pt Times New Roman;margin:0;text-indent:-18pt'>(in thousands except Earnings Per Share)</P>
<TABLE style=border-collapse:collapse;margin-left:-17.1pt><TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2025</FONT></P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2024</FONT></P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$9,710</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'>$11,340</P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'>(14.4%)</P>
</TD></TR>
<TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>5,538</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'>6,766</P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'>(18.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>3,154</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'>3,883</P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'>(18.8%)</P>
</TD></TR>
<TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>3,859</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'>4,798</P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'>(19.6%)</P>
</TD></TR>
<TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>3,041</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'>3,956</P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'>(23.1%)</P>
</TD></TR>
<TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$0.919</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'>$1.093</P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'>(16.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:140.4pt><P style='font:11pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>3,310</P>
</TD><TD valign=top style=width:70.35pt><P align=right style='font:11pt Times New Roman;margin:0'>3,618</P>
</TD><TD valign=top style=width:87.15pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0;text-indent:4.5pt;margin-left:-18pt'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse;margin-left:-15.9pt><TR style=height:21.6pt><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>(unaudited) &nbsp;</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2025</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>(audited)</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2024</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>(unaudited)</P>
<P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2024</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 83,325</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 82,976</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 93,808</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>3,944</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>4,095</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>3,591</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Inventories</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>8,647</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>8,812</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>9,240</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Other Current Assets</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>483</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>448</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>510</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>96,399</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>96,331</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>107,149</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>9,945</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>9,762</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>10,266</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,175</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>16,445</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>18,026</FONT></P>
</TD></TR>
<TR style=height:21.15pt><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$122,519</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$135,441</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>914</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>696</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>998</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>698</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>558</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,712</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2,363</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>3,918</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'> 4,324</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;3,757</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;5,474</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangibles</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>493</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>604</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>986</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Long Term Lease Liability</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>269</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>282</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>285</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>698</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>386</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>468</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>256</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,047</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>117,427</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>127,742</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$122,519</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>$122,538</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$135,441</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20250429_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VEM54XX9]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250429"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250429.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20250429_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VEM54XX9]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250429"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Securities Act File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20250429_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VEM54XX9]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20250429"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20250429.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20250429.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2025 [PPXK5GW761L0VEM54XX9]. www.edgarsuite.com -->
<schema attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://utahmed.com/20250429' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:fil='http://utahmed.com/20250429' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:dei='http://xbrl.sec.gov/dei/2024'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250429_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250429_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20250429_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='https://xbrl.sec.gov/dei/2024/dei-2024.xsd' namespace='http://xbrl.sec.gov/dei/2024'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Apr. 29,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !MTG5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !MTG5K?)! *\    "L"   1
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MAPFM=[NA7<.JO-R!O"D+^YGR= ,[2*Y=![B_4LH>&FY34^U)Q_\"4$L#!!0
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( !MTG5I&QTU(E0   ,T    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ &W2=6M\D$ KP    *P(  !$
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M;',O+G)E;'-02P$"% ,4    "  ;=)U:'#AEZC\!   \ @  #P
M    @ $-$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &W2=6B0>FZ*M
M    ^ $  !H              ( !>1$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ &W2=6F60>9(9 0  SP,  !,
M ( !7A(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  J!,
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20250429.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="utmd-20250429.htm">utmd-20250429.htm</File>
    <File>utmd-20250429.xsd</File>
    <File>utmd-20250429_def.xml</File>
    <File>utmd-20250429_lab.xml</File>
    <File>utmd-20250429_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "utmd-20250429.htm": {
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20250429",
   "dts": {
    "inline": {
     "local": [
      "utmd-20250429.htm"
     ]
    },
    "schema": {
     "local": [
      "utmd-20250429.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20250429_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20250429_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20250429_pre.xml"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 34,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 19
   },
   "report": {
    "R1": {
     "role": "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation",
     "longName": "000010 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D250429",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250429.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D250429",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "utmd-20250429.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiscal Year End",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Period End date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Form",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant CIK",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current with reporting",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Identification Number (TIN)",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary filer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Exchange",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://utahmed.com/20250429/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001096906-25-000625-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-25-000625-xbrl.zip
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MTPN],?SR^!V1:NRSTXS'9>33<34( RU(/JIB6R;2U]SS6)"\AB97\9 )[I*
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M7_Z"J[_@D%$Z4C;]%P;TOU%0^S]02P,$%     @ &W2=6BTK5JW, @  ] @
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M)AP37':U^%4.:"#ZZ.1_95C_#5!+ P04    "  ;=)U:W>IM RL(  #:3@
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MYJJ1-ZB$$K*!3384BGX# 1T!-]0$N%(%>*@+T)6RVO%ID\AHZLZFZ:J 99V
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MT37I_<5>WF#^F'\FN=C[%U!+ P04    "  ;=)U:7J!SHL@C  #UP0  #P
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M+5++&J;=LG_:UP@Y ';\J3Z>?(K".,:-=^>!&_UT]3:8TF^9K\F4RSF/(-2
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M.6C4':1&2J]R!CA<!FSDA?.I&\W<@B7"W!UK7QAD\'$8Q1400\71TE;D(0'
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M[P$_SJ^=%O2 6RN"]>0B&UEW)JN.Y*4.93^\XOP=OBWM&C WC&0U@V)=OM(
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M9"TR,#(U,#0R.2YH=&U02P$"% ,4    "  ;=)U:+2M6K<P"  #T"   $0
M            @ '8#@  =71M9"TR,#(U,#0R.2YX<V102P$"% ,4    "  ;
M=)U:# FD_A<"   F!P  %0              @ '3$0  =71M9"TR,#(U,#0R
M.5]D968N>&UL4$L! A0#%     @ &W2=6MWJ;0,K"   VDX  !4
M     ( !'10  '5T;60M,C R-3 T,CE?;&%B+GAM;%!+ 0(4 Q0    ( !MT
MG5JJRRV$J04  $8T   5              "  7L<  !U=&UD+3(P,C4P-#(Y
M7W!R92YX;6Q02P$"% ,4    "  ;=)U:7J!SHL@C  #UP0  #P
M    @ %7(@  =71M9%]E>#DY>C$N:'1M4$L%!@     &  8 A $  $Q&
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>utmd-20250429_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20250429.xsd" xlink:type="simple"/>
    <context id="D250429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2025-04-29</startDate>
            <endDate>2025-04-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D250429" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D250429" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D250429" id="ixv-354">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D250429" id="ixv-355">2025-04-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D250429" id="ixv-356">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D250429" id="ixv-357">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D250429" id="ixv-358">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D250429" id="ixv-359">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D250429" id="ixv-360">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D250429" id="ixv-361">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D250429" id="ixv-362">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D250429" id="ixv-363">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D250429" id="ixv-364">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D250429" id="ixv-365">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D250429" id="ixv-366">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D250429" id="ixv-367">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D250429" id="ixv-368">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D250429" id="ixv-369">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D250429" id="ixv-370">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
